Source:http://linkedlifedata.com/resource/pubmed/id/21850213
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2011-8-18
|
| pubmed:abstractText |
Purpose: The purpose of this study was to demonstrate the valence of cyclic RGD peptides, P-RGD (PEG(4)-c(RGDfK): PEG(4) = 15-amino-4,710,13-tetraoxapentadecanoic acid), P-RGD(2) (PEG(4)-E[c(RGDfK)](2), 2P-RGD(4) (E{PEG(4)-E[c(RGDfK)](2)}(2), 2P4G-RGD(4) (E{PEG(4)-E[G(3)-c(RGDfK)](2)}(2): G(3) = Gly-Gly-Gly) and 6P-RGD(4) (E{PEG(4)-E[PEG(4)-c(RGDfK)](2)}(2)) in binding to integrin ?(v)?(3), and to assess the impact of peptide and linker multiplicity on biodistribution properties, excretion kinetics and metabolic stability of their corresponding (111)In radiotracers.Methods: Five new RGD peptide conjugates (DOTA-P-RGD (DOTA =1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid), DOTA-P-RGD(2), DOTA-2P-RGD(4), DOTA-2P4G-RGD(4), DOTA-6P-RGD(4)), and their (111)In complexes were prepared. The integrin ?(v)?(3) binding affinity of cyclic RGD conjugates were determined by a competitive displacement assay against (125)I-c(RGDyK) bound to U87MG human glioma cells. Biodistribution, planar imaging and metabolism studies were performed in athymic nude mice bearing U87MG human glioma xenografts.Results: The integrin ?(v)?(3) binding affinity of RGD conjugates follows the order of: DOTA-6P-RGD(4) (IC(50) = 0.3 ± 0.1 nM) ~ DOTA-2P4G-RGD(4) (IC(50) = 0.2 ± 0.1 nM) ~ DOTA-2P-RGD(4) (IC(50) = 0.5 ± 0.1 nM) > DOTA-3P-RGD(2) (DOTA-PEG(4)-E[PEG(4)-c(RGDfK)](2): IC(50) = 1.5 ± 0.2 nM) > DOTA-P-RGD(2) (IC(50) = 5.0 ± 1.0 nM) >> DOTA-P-RGD (IC(50) = 44.3 ± 3.5 nM) ~ c(RGDfK) (IC(50) = 49.9 ± 5.5 nM) >> DOTA-6P-RGK(4) (IC(50) = 437 ± 35 nM). The fact that DOTA-6P-RGK(4) had much lower integrin ?(v)?(3) binding affinity than DOTA-6P-RGD(4) suggests that the binding of DOTA-6P-RGD(4) to integrin ?(v)?(3) is RGD-specific. This conclusion is consistent with the lower tumor uptake for (111)In(DOTA-6P-RGK(4)) than that for (111)In(DOTA-6P-RGD(4)). It was also found that the G(3) and PEG(4) linkers between RGD motifs have a significant impact on the integrin ?(v)?(3)-targeting capability, biodistribution characteristics, excretion kinetics and metabolic stability of (111)In-labeled cyclic RGD peptides.Conclusion: On the basis of their integrin ?(v)?(3) binding affinity and tumor uptake of their corresponding (111)In radiotracers, it was conclude that 2P-RGD(4), 2P4G-RGD(4) and 6P-RGD(4) are most likely bivalent in binding to integrin ?(v)?(3), and extra RGD motifs might contribute to the long tumor retention times of (111)In(DOTA-2P-RGD(4)),( 111)In(DOTA-2P4G-RGD(4)) and (111)In(DOTA-6P-RGD(4)) than that of (111)In(DOTA-3P-RGD(3)) at 72 h p.i. Among the (111)In-labeled cyclic RGD tetramers evaluated in the glioma model, (111)In(DOTA-2P4G-RGD(4)) has very high tumor uptake with the best tumor/kidney and tumor/liver ratios, suggesting that (90)Y(DOTA-2P4G-RGD(4)) and (177)Lu(DOTA-2P4G-RGD(4)) might have the potential for targeted radiotherapy of integrin ?(v)?(3)-positive tumors.
|
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-10452325,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-11280722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-11476168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-12414640,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-12537667,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-14978538,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-15134568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-16204722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-16391195,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-16472190,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-16909226,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-16918408,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-17121909,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-17210459,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-17704249,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-18158950,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-18204838,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-18523069,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-18989988,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-18991712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-19049428,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-19067525,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-19159928,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-19296102,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-19484236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-20857099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21850213-21547160
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:status |
PubMed-not-MEDLINE
|
| pubmed:issn |
1838-7640
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
322-40
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Evaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability.
|
| pubmed:affiliation |
1. School of Health Sciences, Purdue University, IN 47907, USA.
|
| pubmed:publicationType |
Journal Article
|